Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.47 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6860240 | 1.00 | ELANE (0.47) | ELANEPDE1CHTR2CHTTPDK1 | |
| SCHEMBL3076591 | 0.83 | ELANE (0.51) | ELANE | |
| SCHEMBL6409371 | 0.83 | ELANE (0.51) | ELANE | |
| SCHEMBL3076587 | 0.83 | ELANE (0.51) | ELANE | |
| SCHEMBL7020603 | 0.81 | ELANE (0.38) | ELANEPDE1CHTR2CHTTNPC1 | |
| SCHEMBL7020601 | 0.81 | ELANE (0.38) | ELANEPDE1CHTR2CHTTNPC1 | |
| SCHEMBL30904956 | 0.81 | ELANE (0.43) | ELANEPDE1CHTR2C | |
| SCHEMBL3079101 | 0.80 | ELANE (0.52) | ELANESMN1; SMN2ALDH1A1 | |
| SCHEMBL3079099 | 0.80 | ELANE (0.52) | ELANESMN1; SMN2ALDH1A1 | |
| SCHEMBL5516075 | 0.80 | ELANE (0.52) | ELANESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794523-B2 | ANTICANCER AGENTS, ANTITUMOR AGENTS; LEUKEMIA | FLORIDA STATE UNIVERSITY | 2004-09-21 | — | — | US | disclosed |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | FLORIDA STATE UNIVERSITY | 2003-04-03 | — | — | US | disclosed |
| US-6018073-A | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5739362-A | ANTILEUKEMIA, ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY (US) | 1998-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | MCL1, BCL3, TOP2A | ELANE 671/4885PDE1C 4812/4885HTR2C 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.